Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Recombinant RSV (Palivizumab Biosimilar) anticorps

Reactivité: Humain FACS, in vivo Hôte: Souris Monoclonal unconjugated Recombinant Antibody
N° du produit ABIN7200664
  • Antigène Tous les produits RSV (Palivizumab Biosimilar)
    RSV (Palivizumab Biosimilar)
    Type d'anticorp
    Recombinant Antibody
    Reactivité
    Humain
    Hôte
    • 1
    Souris
    Clonalité
    • 1
    Monoclonal
    Conjugué
    • 1
    Cet anticorp RSV (Palivizumab Biosimilar) est non-conjugé
    Application
    Flow Cytometry (FACS), In vivo Studies (in vivo)
    Fonction
    Palivizumab Biosimilar, RSV Monoclonal Antibody
    Specificité
    The monoclonal antibody palivizumab biosimilar specifically binds to an epitope in the A antigenic site of the F protein of RSV (respiratory syncytial virus).
    Attributs du produit
    Recombinant Humanized IgG1 Monoclonal Antibody.
    Purification
    Protein A affinity column
    Pureté
    > 95% by SDS-PAGE under reducing conditions and HPLC.
    Stérilité
    0.2 μm filtered
    niveau d'endotoxine
    < 1 EU per 1 mg of the protein by the LAL method.
    Immunogène
    The monoclonal antibody palivizumab biosimilar was produced in the palivizumab biosimilar CHO stable cell line.
    Isotype
    IgG1 kappa
  • Indications d'application
    ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by palivizumab.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1 mg/mL
    Buffer
    PBS, pH 7.4, no stabilizers or preservatives.
    Agent conservateur
    Without preservative
    Conseil sur la manipulation
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    Stock
    -20 °C
    Stockage commentaire
    12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
    Date de péremption
    12 months
  • Antigène
    RSV (Palivizumab Biosimilar)
    Abstract
    RSV (Palivizumab Biosimilar) Produits
    Classe de substances
    Biosimilar
    Sujet
    Palivizumab, a humanized anti-RSV (respiratory syncytial virus) monoclonal antibody, targets an epitope in the A antigenic site of the F protein of RSV, inhibiting its entry into the cell and thereby preventing infection.
Vous êtes ici:
Support technique